2013
DOI: 10.3892/mmr.2013.1370
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The overexpression of peroxiredoxins (prxs) has been shown to be associated with the development, progression and drug resistance of cancer. However, the role of the prxs in the drug resistance of ovarian cancer is unknown. The present study aimed to investigate the effect and mechanism of the downregulation of PRDX3 on cisplatin‑induced ovarian cancer cell apoptosis. The expression of PRDX3 in ovarian cancer was examined by immunohistochemistry. The effect on cisplatin‑induced ovarian cancer apoptosis by the … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
20
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 22 publications
(20 citation statements)
references
References 21 publications
0
20
0
Order By: Relevance
“…In T lymphoma cells treated with isothiocyanate or auranofin, PRX3 was selectively oxidized, followed by disruption of mitochondrial redox homeostasis and subsequent apoptosis of cancer cells (Brown et al 2008;Cox et al 2008a). Silencing Duan et al (2013) of the PRX3 expression in human neuroblastoma cells sensitized the cells to oxidative damages and apoptosis induced by 1-methyl-4-phenylpyridinium (MPP+) (De Simoni et al 2008). According to the report by Vivas-Mejía et al, the expression of PRX3 was down-regulated and the apoptosis was enhanced in the acute promyelocytic leukemia (APL)-derived cells treated with arsenic trioxide (ATO) (VivasMejía et al 2009).…”
Section: The Expression Of Prx3 and Its Involvement In Apoptosis Of Cmentioning
confidence: 94%
See 1 more Smart Citation
“…In T lymphoma cells treated with isothiocyanate or auranofin, PRX3 was selectively oxidized, followed by disruption of mitochondrial redox homeostasis and subsequent apoptosis of cancer cells (Brown et al 2008;Cox et al 2008a). Silencing Duan et al (2013) of the PRX3 expression in human neuroblastoma cells sensitized the cells to oxidative damages and apoptosis induced by 1-methyl-4-phenylpyridinium (MPP+) (De Simoni et al 2008). According to the report by Vivas-Mejía et al, the expression of PRX3 was down-regulated and the apoptosis was enhanced in the acute promyelocytic leukemia (APL)-derived cells treated with arsenic trioxide (ATO) (VivasMejía et al 2009).…”
Section: The Expression Of Prx3 and Its Involvement In Apoptosis Of Cmentioning
confidence: 94%
“…One of the underlying mechanism for the activity might be that TS disabled the TR2/TRX2/PRX3 mitochondrial antioxidant pathway by covalently adducting cysteine residues in PRX3 as evidenced in MM cells (Newick et al 2012). In ovarian cancer cells, siRNA targeting of PRX3 expression enhanced cisplatin-induced apoptosis (Duan et al 2013). In summary, the anticancer drugs or potential anticancer chemicals induced apoptosis of cancer cells by increasing ROS level and oxidizing PRX3, inactivating PRX3 antioxidant activity, or down-regulating PRX3 expression, which suggested that PRX3 might be potentially targeted for chemotherapeutic effects.…”
Section: The Expression Of Prx3 and Its Involvement In Apoptosis Of Cmentioning
confidence: 99%
“…Peroxiredoxins (Prxs) have been shown to be involved in the development, progression and drug resistance of cancers [11,12]. As a member of the Prx family, Prx3 contains a mitochondrial localization sequence, is found exclusively in the mitochondrion, and uses mitochondrial thioredoxin-2 as the electron donor for its peroxidase activity [13].…”
Section: Introductionmentioning
confidence: 99%
“…Li and co-workers have previously reported that the expression of PRDX3 was up-regulated in ovarian serous cystadenocarinoma specimens when compared with the normal ovarian epithelia [56]. In addition, Duan et al [60] observed that the expression of PRDX3 was significantly higher in cancer tissues than the adjacent non-cancerous tissues, and high PRDX3 levels in serous ovarian carcinoma were related to poorly differentiated cancer cells, FIGO stages III and IV, which suggests that aberrant expression of PRDX3 is significantly associated with the progression of ovarian cancer. Wang et al [61] found that PRDX3 expression was significantly higher in the platinum-resistant serous ovarian cancer, in stages III and IV, and in moderately and poorly differentiated ovarian cancer tissues compared with their platinum-sensitive counterparts, they therefore concluded that PRDX3 was associated with drug resistance in ovarian cancer.…”
Section: Discussionmentioning
confidence: 99%
“…As antioxidants, PRDXs have been shown to be related to chemotherapy drug resistance of cancers. PRDX3 expression was associated with platinum resistance in ovarian cancer, and siRNA targeting of PRDX3 triggered cisplatin–induced apoptosis in SKOV3 ovarian cancer cells through suppression of the NF–κB signaling pathway [60,61]. Furthermore, overexpression of PRDX6 attenuated cisplatin-induced apoptosis by reducing ROS levels in SKOV-3 ovarian cancer cells and led to the development of cisplatin resistance [74].…”
Section: Discussionmentioning
confidence: 99%